- Home
- CRDF vs IMMP Comparison
CRDF vs IMMP Comparison
Compare CRDF & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- IMMP
- Stock Information
- Founded
- CRDF 1999
- IMMP 1987
- Country
- CRDF United States
- IMMP Australia
- Employees
- CRDF N/A
- IMMP N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- IMMP Health Care
- Exchange
- CRDF Nasdaq
- IMMP Nasdaq
- Market Cap
- CRDF 233.5M
- IMMP 244.5M
- IPO Year
- CRDF N/A
- IMMP N/A
- Fundamental
- Price
- CRDF $2.64
- IMMP $1.72
- Analyst Decision
- CRDF Strong Buy
- IMMP Buy
- Analyst Count
- CRDF 6
- IMMP 1
- Target Price
- CRDF $11.92
- IMMP $7.00
- AVG Volume (30 Days)
- CRDF 3.0M
- IMMP 75.4K
- Earning Date
- CRDF 07-29-2025
- IMMP 02-27-2025
- Dividend Yield
- CRDF N/A
- IMMP N/A
- EPS Growth
- CRDF N/A
- IMMP N/A
- EPS
- CRDF N/A
- IMMP N/A
- Revenue
- CRDF $545,000.00
- IMMP $3,019,249.00
- Revenue This Year
- CRDF N/A
- IMMP $50.37
- Revenue Next Year
- CRDF N/A
- IMMP N/A
- P/E Ratio
- CRDF N/A
- IMMP N/A
- Revenue Growth
- CRDF N/A
- IMMP 24.11
- 52 Week Low
- CRDF $2.01
- IMMP $1.32
- 52 Week High
- CRDF $5.64
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- CRDF 34.68
- IMMP 50.65
- Support Level
- CRDF $2.31
- IMMP $1.60
- Resistance Level
- CRDF $4.52
- IMMP $1.81
- Average True Range (ATR)
- CRDF 0.37
- IMMP 0.06
- MACD
- CRDF -0.21
- IMMP 0.01
- Stochastic Oscillator
- CRDF 14.67
- IMMP 52.17
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.